White Paper: What’s Next for Cell and Gene Therapies in 2023 and Beyond
The cell and gene therapy (CGTx) sector has flourished in recent years due to continued investor confidence. However, the present downturn in public markets has negatively affected that confidence, raising questions about the sector’s prospects for 2023 and beyond.
This white paper is based on a panel discussion at the Cell & Gene Meeting on the Mesa (October 11, 2022), sponsored by Precision ADVANCE, focusing on the future of advanced therapies. The panel included insights from the following industry leaders:
- Anshul Mangal: President (Project Farma & Precision ADVANCE)
- Stewart Abbot: Chief Scientific Officer (Turnstone Biologics)
- Laura Lande-Diner: Chief Business Officer (Satellite Bio)
- Robert Peters: Chief Scientific Officer (Ensoma)
- Deborah Phippard: Chief Scientific Officer (Precision For Medicine)
White Paper: State of the Union for Advanced Medicines
The cell and gene therapy (CGTx) sector has flourished over the last 2 to 5 years due to continued investor confidence. However, the recent downturn in public markets has undermined that confidence.
This white paper is based on a panel discussion, sponsored by Precision ADVANCE, featuring insights from diverse industry perspectives on the current state of the CGTx sector; the investment landscape; scientific and technical advances; progress in drug development, manufacturing, regulatory, pricing, and reimbursement; and expected key trends in 2023 and beyond. Hosted by Endpoints News, the panel included insights from the following industry leaders:
- Anshul Mangal: President (Project Farma & Precision ADVANCE)
- Dave Greenwald: Vice President of Business Development (Deerfield Management)
- Rajul Jain: Managing Director (Vida Ventures)
- Joseph LaBarge: Chief Executive Officer (Apertura Gene Therapy)
- Adrian Woolfson: Executive Chairman, President and Co-Founder (Replay Bio)
- Phil Cyr: Executive Vice President (Precision Value & Health)
QuartzBio, a Part of Precision for Medicine, Acquires SolveBio and Expands Software-as-a-Service (SaaS) Data Management Solutions for Clinical Research & Development (R&D)
QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity.
[Frederick, MD – January 24, 2023] Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio.
SolveBio’s intelligent technologies and enterprise data management platform has integrated into QuartzBio’s suite of SaaS solutions, providing a single, scalable solution supporting clinical sample inventory management and biomarker data management for the biotech and pharmaceutical sectors.
PRECISION VALUE & HEALTH NAMES DOUG FULLING PRESIDENT
Proven Life Sciences Leader Takes Reins to Continue Rapid Growth and
Drive Next-Gen Commercialization Model
BETHESDA, MD (January 26, 2023) Precision Value & Health (PVH), today announces that Doug Fulling has joined as President. As the industry leader in delivering complementary, integrated and specialized capabilities across the commercialization continuum, Doug will be accountable for the overall strategy, organizational leadership, financial performance, and next-level growth of this market-leading commercial enterprise.
New Tech on the Rise: The Future of Cell and Gene Therapies Is Here
Recent headlines suggest that the biotech industry as a whole is experiencing a downturn, yet in spite of this narrative the momentum for advanced therapies continues to persevere. Many companies in the cell and gene therapy space are dedicated to bringing these novel therapies to the patients who need them. In this article for PM360 Magazine, Precision’s Anshul Mangal explores the breakthroughs taking place in autologous cell therapies, non-viral delivery methods, and gene editing technologies that may improve patient access for life-saving treatments.